PDF(Pubmed)
Abstract：
High Tumor Necrosis Factor Receptor 2 (TNFR2) expression is characteristic of diverse malignant cells during tumorigenesis. The protein is also expressed by many immunosuppressive cells during cancer development, allowing cancer immune escape. A growing body of evidence further suggests a correlation between the circulating form of this protein and cancer development. Here we conducted a systematic meta-analysis of cancer studies published up until 1st October 2022, in which the circulating soluble TNFR2 (sTNFR2) concentrations in patients with cancers were recorded and their association with cancer risk was assessed. Of the 14,615 identified articles, 44 studies provided data on the correlation between cancer risk and the level of circulating sTNFR2. The pooled means comparison showed a consistently significant increase in the levels of sTNFR2 in diverse cancers when compared to healthy controls. These included colorectal cancer, ovarian cancer, breast cancer, non-Hodgkin\'s lymphoma, Hodgkin\'s lymphoma, lung cancer, hepatocarcinoma, and glioblastoma. In a random-effect meta-analysis, the cancer-specific odd ratios (OR) showed significant correlations between increased circulating sTNFR2 levels and the risk of colorectal cancer, non-Hodgkin\'s lymphoma, and hepatocarcinoma at 1.59 (95% CI:1.20-2.11), 1.98 (95% CI:1.49-2.64) and 4.32 (95% CI:2.25-8.31) respectively. The overall result showed an association between circulating levels of sTNFR2 and the risk of developing cancer at 1.76 (95% CI:1.53-2.02). This meta-analysis supports sTNFR2 as a potential diagnostic biomarker for cancer, albeit with different predictive strengths for different cancer types. This is consistent with a potential key role for TNFR2 involvement in cancer development.
摘要：
肿瘤坏死因子受体2（TNFR2）的高表达是肿瘤发生过程中多种恶性细胞的特征。该蛋白在癌症发展过程中也被许多免疫抑制细胞表达，允许癌症免疫逃逸。越来越多的证据进一步表明，这种蛋白质的循环形式与癌症发展之间存在相关性。在这里，我们对2022年10月1日之前发表的癌症研究进行了系统的荟萃分析，其中记录了癌症患者的循环可溶性TNFR2（sTNFR2）浓度，并评估了其与癌症风险的关系。在14,615篇文章中，44项研究提供了有关癌症风险与循环sTNFR2水平之间相关性的数据。合并平均值比较显示,当与健康对照相比时,在多种癌症中sTNFR2的水平持续显著增加。这些包括结直肠癌，卵巢癌,乳腺癌,非霍奇金淋巴瘤,霍奇金淋巴瘤,肺癌,肝癌，和胶质母细胞瘤.在随机效应荟萃分析中，癌症特异性奇数比（OR）显示循环sTNFR2水平升高与结直肠癌风险之间存在显著相关性，非霍奇金淋巴瘤,肝癌为1.59（95%CI：1.20-2.11），分别为1.98（95%CI：1.49-2.64）和4.32（95%CI：2.25-8.31）。总体结果显示，sTNFR2的循环水平与1.76（95％CI：1.53-2.02）患癌症的风险之间存在关联。这项荟萃分析支持sTNFR2作为癌症的潜在诊断生物标志物，尽管对不同癌症类型具有不同的预测优势。这与TNFR2参与癌症发展的潜在关键作用一致。
